Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.

Of 602 patients treated for non-Hodgkin's lymphomas, 9 developed overt acute nonlymphocytic leukemia or preleukemia with refractory cytopenia and cytogenetic abnormalities of the bone marrow. A Kaplan-Meier estimate of the cumulative probability of leukemic complications was 6.3 +/- 2.6% (mean +/- SE) 7 years after start of treatment. All 9 patients with leukemic complications belong to a major subgroup of 498 patients treated with alkylating agents, predominantly cyclophosphamide. The risk of leukemic complications in this subgroup was compared with the risk in 312 patients treated with other alkylating agents for Hodgkin's disease, and with the risk in 553 patients treated with dihydroxybusulfan for ovarian carcinoma. Cumulative 9-year risks were 8.0 +/- 3.3%, 12.8 +/- 3.5%, and 7.1 +/- 1.9%, respectively. The general risk of secondary leukemia after long-term treatment with alkylating agents ranges from 1% to 1.5% per year from 2 to at least 9 years after start of treatment.

[1]  N. Nissen,et al.  A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I‐II non‐hodgkin's lymphomas , 2006, Cancer.

[2]  M. Ro̸rth,et al.  Acute nonlymphocytic leukemia following treatment of testicular cancer and gastric cancer with combination chemotherapy not including alkylating agents: Report of two cases , 1985, American journal of hematology.

[3]  N. Nissen,et al.  Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. II. Bone marrow cytology, cytogenetics, results of HLA typing, response to antileukemic chemotherapy, and survival in a total series of 55 patients , 1984, Cancer.

[4]  R J Keehn,et al.  Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). , 1983, The New England journal of medicine.

[5]  A. Aisenberg.  Acute nonlymphocytic leukemia after treatment for Hodgkin's disease. , 1983, The American journal of medicine.

[6]  M. Greene,et al.  Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. , 1983, Cancer research.

[7]  M. Greene,et al.  Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized clinical trials. , 1982, The New England journal of medicine.

[8]  T. Han,et al.  Post‐therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non‐Hodgkin's lymphoma correlation with intensity of treatment , 1982, Cancer.

[9]  S. Larsen,et al.  Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. , 1982, The New England journal of medicine.

[10]  T. Pajak,et al.  Second malignant neoplasms in patients successfully treated for Hodgkin's disease: a Cancer and Leukemia Group B study. , 1982, Cancer treatment reports.

[11]  A. Santoro,et al.  Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease. , 1982, Blood.

[12]  B. Weinerman,et al.  Second malignancies in non‐Hodgkin's lymphoma , 1981, Cancer.

[13]  J. Pedersen‐Bjergaard,et al.  Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. Clinical and cytogenetic characteristics and results of in vitro culture of bone marrow and HLA typing. , 1981, Blood.

[14]  J. Goldberg,et al.  Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. , 1981, The New England journal of medicine.

[15]  G. Hutchison,et al.  Leukemia in women following radiotherapy for cervical cancer: ten-year follow-up of an international study. , 1980, Journal of the National Cancer Institute.

[16]  M. Weil,et al.  Post‐therapeutic acute leukemia , 1979, Cancer.

[17]  D. Girling,et al.  Acute leukaemia after busulphan. , 1977, British medical journal.

[18]  T. Pajak,et al.  Overview of four clinical studies of chemotherapy for stage III and IV non-Hodgkin's lymphomas by the Cancer and Leukemia Group B. , 1977, Cancer treatment reports.

[19]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[20]  M Tubiana,et al.  Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.

[21]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[22]  G. Bonadonna,et al.  Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  N. Nissen,et al.  Acute non‐lymphocytic leukemia in patients with ovarian carcinoma following long‐term treatment with treosulfan (=dihydroxybusulfan) , 1980, Cancer.